Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Wyllie

Showing results (81-90 of 94) with videos related to

Pageof 10
Sort By:
ACS Medicinal Chemistry Letters|April 16, 2020
New 8-Nitroquinolinone Derivative Displaying Submicromolar <i>in Vitro</i> Activities against Both <i>Trypanosoma brucei</i> and <i>cruzi</i>Julien Pedron, Clotilde Boudot, Jean-Yves Brossas, et al.
Journal of Medicinal Chemistry|June 21, 2023
Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of AnaloguesLaura A T Cleghorn, Richard J Wall, Sébastien Albrecht, et al.
European Journal of Medicinal Chemistry|August 16, 2020
Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic propertiesCyril Fersing, Clotilde Boudot, Romain Paoli-Lombardo, et al.
Trends in Parasitology|March 2, 2021
MalDA, Accelerating Malaria Drug DiscoveryTuo Yang, Sabine Ottilie, Eva S Istvan, et al.
European Journal of Medicinal Chemistry|July 12, 2020
8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruziCyril Fersing, Clotilde Boudot, Caroline Castera-Ducros, et al.
Science Translational Medicine|July 9, 2025
Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas diseaseLindsay B Tulloch, Hugh Tawell, Annie E Taylor, et al.
Journal of Medicinal Chemistry|March 18, 2022
Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal TrypanosomiasisAlasdair Smith, Richard J Wall, Stephen Patterson, et al.
Science Translational Medicine|December 13, 2023
Short-course combination treatment for experimental chronic Chagas diseaseSilvia González, Richard J Wall, John Thomas, et al.
Nature Communications|March 17, 2023
Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formationSelina Bopp, Charisse Flerida A Pasaje, Robert L Summers, et al.
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Pageof 10

Showing results (81-90 of 94) with videos related to

Sort By:
Pageof 10
ACS Medicinal Chemistry Letters|April 16, 2020
New 8-Nitroquinolinone Derivative Displaying Submicromolar <i>in Vitro</i> Activities against Both <i>Trypanosoma brucei</i> and <i>cruzi</i>Julien Pedron, Clotilde Boudot, Jean-Yves Brossas, et al.
Journal of Medicinal Chemistry|June 21, 2023
Development of a 2,4-Diaminothiazole Series for the Treatment of Human African Trypanosomiasis Highlights the Importance of Static-Cidal Screening of AnaloguesLaura A T Cleghorn, Richard J Wall, Sébastien Albrecht, et al.
European Journal of Medicinal Chemistry|August 16, 2020
Antikinetoplastid SAR study in 3-nitroimidazopyridine series: Identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic propertiesCyril Fersing, Clotilde Boudot, Romain Paoli-Lombardo, et al.
Trends in Parasitology|March 2, 2021
MalDA, Accelerating Malaria Drug DiscoveryTuo Yang, Sabine Ottilie, Eva S Istvan, et al.
European Journal of Medicinal Chemistry|July 12, 2020
8-Alkynyl-3-nitroimidazopyridines display potent antitrypanosomal activity against both T. b. brucei and cruziCyril Fersing, Clotilde Boudot, Caroline Castera-Ducros, et al.
Science Translational Medicine|July 9, 2025
Antitrypanosomal quinazolines targeting lysyl-tRNA synthetase show partial efficacy in a mouse model of acute Chagas diseaseLindsay B Tulloch, Hugh Tawell, Annie E Taylor, et al.
Journal of Medicinal Chemistry|March 18, 2022
Repositioning of a Diaminothiazole Series Confirmed to Target the Cyclin-Dependent Kinase CRK12 for Use in the Treatment of African Animal TrypanosomiasisAlasdair Smith, Richard J Wall, Stephen Patterson, et al.
Science Translational Medicine|December 13, 2023
Short-course combination treatment for experimental chronic Chagas diseaseSilvia González, Richard J Wall, John Thomas, et al.
Nature Communications|March 17, 2023
Potent acyl-CoA synthetase 10 inhibitors kill Plasmodium falciparum by disrupting triglyceride formationSelina Bopp, Charisse Flerida A Pasaje, Robert L Summers, et al.
Nature|July 27, 2018
Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasisSusan Wyllie, Michael Thomas, Stephen Patterson, et al.
Pageof 10